Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 .
Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell. | August 11, 2022
Total revenues increased 4% in H1 2022 to US$96.8 million, supported by increases in physicians prescribing and number of patients Strong balance sheet and stable cash flow from RUCONEST providing
Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18.
Checkpoint Therapeutics (CKPT) Granted Pediatric Investigational Plan Waivers for Cosibelimab in Europe and UK streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.